| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SCDO1 |
| Entrez GeneID | 10683 |
| clone | 6H4C4 |
| WB Predicted band size | 65KDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Purified recombinant fragment of human DLL3 (AA: EXTRA(27-226)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于DLL3抗体的3篇代表性文献的简要信息：
1. **文献名称**：*DLL3: An Emerging Target in Small Cell Lung Cancer*
**作者**：Saunders LR, et al.
**摘要**：该研究探讨了DLL3在小细胞肺癌(SCLC)中的高表达及其作为治疗靶点的潜力，并介绍了靶向DLL3的抗体药物偶联物(ADC)Rovalpituzumab Tesirine(Rova-T)的临床前数据，显示其在肿瘤模型中的显著抗肿瘤活性。
2. **文献名称**：*Rovalpituzumab Tesirine, a DLL3-Targeted Antibody-Drug Conjugate, in Recurrent Small-Cell Lung Cancer: A First-in-Human, First-in-Class, Open-Label, Phase 1 Study*
**作者**：Rudin CM, et al.
**摘要**：这项I期临床试验评估了Rova-T在复发SCLC患者中的安全性和初步疗效，结果显示部分患者达到客观缓解，验证了DLL3作为治疗靶点的可行性，但也提示需关注后续耐药性和毒性问题。
3. **文献名称**：*DLL3 as a Therapeutic Target in High-Grade Neuroendocrine Tumors*
**作者**：Puca L, et al.
**摘要**：研究分析了DLL3在高级别神经内分泌肿瘤中的表达特征，并开发了一种新型双特异性抗体，可同时靶向DLL3和CD3.通过激活T细胞实现肿瘤特异性杀伤，为免疫疗法提供了新思路。
4. **文献名称**：*Structural Basis of Notch Recognition by Human DLL3*
**作者**：Ladi E, et al.
**摘要**：通过解析DLL3蛋白的晶体结构，揭示了其与Notch受体相互作用的分子机制，为设计高特异性DLL3抗体及优化靶向药物的结合能力提供了结构生物学依据。
这些文献涵盖了DLL3抗体的基础机制、药物开发及临床转化研究，反映了其在肿瘤治疗中的研究进展与挑战。
**Background of DLL3 Antibodies**
DLL3 (Delta-like protein 3) is a ligand in the Notch signaling pathway, primarily involved in cell differentiation and development. Unlike other Delta-like family members, DLL3 is atypically localized in the Golgi apparatus and exhibits limited surface expression in normal tissues. However, DLL3 is frequently overexpressed in neuroendocrine tumors, such as small cell lung cancer (SCLC), large cell neuroendocrine carcinoma, and neuroendocrine prostate cancer, making it a promising therapeutic target.
DLL3-targeted antibodies, particularly antibody-drug conjugates (ADCs) and bispecific antibodies, have emerged as potential therapies. Rovalpituzumab tesirine (Rova-T), an ADC linking an anti-DLL3 antibody to a cytotoxic payload, showed early promise in SCLC but faced setbacks in clinical trials due to limited efficacy and toxicity. Despite this, research continues to explore improved DLL3-targeting strategies, including bispecific antibodies engaging T cells (e.g., DLL3-CD3 bispecifics) and combination therapies with immune checkpoint inhibitors.
Challenges include understanding DLL3's role in Notch pathway regulation, addressing tumor heterogeneity, and mitigating resistance mechanisms linked to Notch activation. Ongoing studies aim to refine targeting approaches, enhance therapeutic windows, and identify predictive biomarkers to optimize patient selection. DLL3 remains a compelling focus in precision oncology for neuroendocrine malignancies.
×
